NCT02643303 2022-12-02A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersLudwig Institute for Cancer ResearchPhase 1/2 Completed58 enrolled 24 charts
NCT01984892 2018-01-23HiltonolIcahn School of Medicine at Mount SinaiPhase 2 Terminated8 enrolled 4 charts